A Phase 2 Trial of Cryosurgical Freezing and Intratumoral Combination Immunotherapy in Men With Metastatic Prostatic Adenocarcinoma
Latest Information Update: 24 Jun 2022
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
- Focus Therapeutic Use
- 15 Jun 2022 Status changed from discontinued to completed.
- 04 Feb 2022 Status changed from recruiting to discontinued.
- 17 Sep 2019 New trial record